Intismeran Autogene

Intismeran Autogene is a personalized mRNA cancer vaccine developed by moderna and Merck & Co. for the treatment of resected melanoma. It functions as an adjuvant therapy, designed to stimulate the immune system to recognize and attack tumor-specific neoantigens following surgical removal of the primary tumor.

Key Developments

• Clinical Trial Results: Positive Phase 3 trial results were announced in 2026, demonstrating efficacy in preventing recurrence in patients with resected melanoma.
• Combination Therapy: The vaccine is administered in conjunction with Keytruda (pembrolizumab), a PD-1 inhibitor, to enhance anti-tumor immune response.
• Personalization: As an mRNA vaccine, Intismeran Autogene is tailored to the specific mutational profile of each patient’s tumor.

References

• Moderna Merck mRNA Cancer Vaccine and Keytruda for Resected Melanoma Adjuvant Therapy
• How Big of a Deal is this Cancer Vaccine? by Hank Green